PART 4 – SUMMARY OF EVIDENCE Provide an overview of all key journal articles or research published in the public domain related to the proposed service that is for your application (limiting these to the English language only). Please do not attach full text articles, this is just intended to be a summary. Type of study design* Title of journal article or Short description of Website link to journal article or research (if Date of research project (including research (max 50 available) publication*** any trial identifier or study words)** lead if relevant) ALL 1. NCT01626495: A phase Mueller, K. et al. Cellular Cellular kinetic https://www.ncbi.nlm.nih.gov/pubmed/28935694 2017 I/IIA study of two kinetics of CTL019 in analyses of CTL019 in a different kinds of relapsed/refractory B-cell cohort of 103 patients CART19 cells for 76 acute lymphoblastic leukemia with ALL or CLL treated patients aged 1-24 and chronic lymphocytic across three clinical years with leukemia. Blood. 2017 (Sep studies. chemotherapy 21). NCT01626495, resistant or refractory NCT01747486 & CD19+ leukemia and NCT01029366. lymphoma. 2. Maude, S. et al. Chimeric Analysis of outcomes https://www.ncbi.nlm.nih.gov/pubmed/25317870 2014 antigen receptor T cells for for 25 paediatric and 5 systained remission in adult patients with lukaemia. N Engl J Med. relapsed or refractory 2014;371(16):1507. ALL recruited across NCT01626495 & NCT01029366 two Phase I/II clinical NCT01029366: A pilot, trials.
PART 4 – SUMMARY OF EVIDENCE Provide an overview of all key journal articles or research published in the public domain related to the proposed service that is for your application (limiting these to the English language only). Please do not attach full text articles, this is just intended to be a summary. Type of study design* Title of journal article or research project (including any trial identifier or study lead if relevant) Short description of research (max 50 words)** Website link to journal article or research (if available) Date of publication*** ALL 1. NCT01626495: A phase I/IIA study of two different kinds of CART19 cells for 76 patients aged 1-24 years with chemotherapy resistant or refractory CD19+ leukemia and lymphoma. NCT01029366: A pilot, Mueller, K. et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017 (Sep 21). NCT01626495, NCT01747486 & NCT01029366. Cellular kinetic analyses of CTL019 in a cohort of 103 patients with ALL or CLL treated across three clinical studies. https://www.ncbi.nlm.nih.gov/pubmed/28935694 2017 2. Maude, S. et al. Chimeric antigen receptor T cells for systained remission in lukaemia. N Engl J Med. 2014;371(16):1507. NCT01626495 & NCT01029366 Analysis of outcomes for 25 paediatric and 5 adult patients with relapsed or refractory ALL recruited across two Phase I/II clinical trials. https://www.ncbi.nlm.nih.gov/pubmed/25317870 2014